landmark Shift in Cervical Cancer Screening: Self-collection Now Endorsed for Average-Risk Individuals
Table of Contents
The American Cancer Society (ACS) has substantially updated its cervical cancer screening guidelines, endorsing self-collected vaginal specimens for human papillomavirus (HPV) testing – a move poised to increase access and equity in preventative care.
The updated guidelines, released this week, allow individuals between the ages of 25 and 65 who are at average risk to collect their own samples in clinical settings, and in limited cases, at home using FDA-approved kits. This represents a major departure from traditional methods relying on clinician-collected samples during pelvic exams.
Addressing Barriers to Screening
Historically, cervical cancer screening has faced notable hurdles related to access and patient comfort. Traditional methods, involving a pelvic exam for a Pap smear, HPV testing, or both, can be a barrier for those experiencing discomfort, limited access to healthcare, or other obstacles. According to one women’s health advocate, “This is significant because over 1 in 4 U.S. females are behind on screening, with 32% citing discomfort as a barrier.”
HPV testing using self-collected specimens is now possible with several approved methods:
- BD onclarity HPV test with FLOQSwab
- Abbott Alinity m with Evalyn brush or Qvintip swab
- Teal Wand for at-home use with the Roche cobas HPV test (through a proprietary telehealth service)
If a self-collected HPV test result is negative, repeat screening is advised in three years – a shorter interval than the five years recommended for clinician-collected HPV tests. The ACS describes this as a “margin of safety” while awaiting further long-term U.S. data on the performance of self-collection methods.
Revised Exit Criteria for older Adults
The updated guidelines also address long-standing concerns regarding unclear criteria for discontinuing cervical cancer screening after age 65. Approximately one-quarter of cervical cancer cases in the U.S. occur in women over 65,with mortality rates double those of younger women – a trend linked to inadequate screening in the years leading up to cessation.
Previously, the ACS recommended ending screening at age 65 with a documented history of adequate negative tests within the prior 10 years.Tho, incomplete medical records frequently enough hindered the practical submission of this guideline.
The new suggestion adopts a forward-looking approach: average-risk individuals should have negative primary HPV tests (preferred) or negative co-tests at both ages 60 and 65 before stopping screening. Alternatively,three consecutive negative Pap tests at the recommended interval,with the last test administered at age 65,are also acceptable.For those utilizing self-collected HPV testing, the three-year interval applies.
Screening should continue beyond age 65 for individuals with specific risk factors, including HIV, immunosuppression, abnormal results within the past 10 years, cervical precancer within the past 25 years, or a history of cervical cancer.
Critically important Considerations and Ongoing Research
Self-collection is not a replacement for clinician collection for higher-risk groups, such as those with HIV, immunosuppression, prior cervical cancer, or in utero exposure to diethylstilbestrol (DES). These patients require both HPV and cytology testing, and cytology cannot be performed on self-collected specimens.
“Patients need to understand that they now have the option to collect their own vaginal specimen for HPV testing at home or in a clinical setting,” one senior official stated, “but this requires more frequent screening than traditional clinician-collected samples.” another expert added that while self-collection is acceptable, clinician-collected cervical specimens remain preferred.
The ACS aims to make cervical cancer screening more flexible, accessible, and effective by incorporating self-collection and simplifying exit criteria, while maintaining safety through clear follow-up protocols and risk-based decision-making.As one advocate noted, “Multiple testing options also increase the likelihood that patients will actually get screened by meeting them where they are,” particularly benefiting those in rural areas, trauma survivors, and individuals uncomfortable with traditional pelvic exams.